Results 61 to 70 of about 5,633 (190)
Acta Ophthalmologica, EarlyView.Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen +3 more
wiley +1 more source
Alopurinol vs Febuxostat: Revisión bibliográfica [PDF]
, 2020 En el tratamiento de la hiperuricemia se utilizan dos fármacos principalmente, ambos inhibidores de la enzima xantina oxidasa, el alopurinol y el febuxostat.
Alvite Geraldes, Beatriz
core
Pharmacology Research & PerspectivesThe study objective was to validate febuxostat dosage and administration in pediatric patients with hyperuricemia including gout, using an integrated population pharmacokinetic (PopPK) analysis in the Japanese population.
Ryutaro Iwama +3 more
doaj +1 more source
African American patients with gout: efficacy and safety of febuxostat vs allopurinol
BMC Musculoskeletal Disorders, 2012 Background African Americans are twice as likely as Caucasians to develop gout, but they are less likely to be treated with urate-lowering therapy (ULT).
Wells Alvin F +3 more
doaj +1 more source
A 32‐Year‐Old Man With an Cardiomyopathy
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT Scleredema is a sclerosing dermatosis of unknown etiology, characterized by non‐punctate, weakly infiltrated skin thickening and swelling, which can lead to the development of cardiomyopathy. Scleredema‐associated cardiomyopathy is at present poorly understood.
Yuting Zou, Shan Li, Tong Chen, Yi Li
wiley +1 more source
Clinical pharmacokinetics and pharmacodynamics of febuxostat
, 2017 Febuxostat is a xanthine oxidoreductase inhibitor that has been developed to treat chronic gout. In healthy subjects, the pharmacokinetic parameters of febuxostat after multiple oral dose administration include an oral availability of about 85Â %, an ...
Williams, Kenneth M. +4 more
core +1 more source
Revisiting the Ethics of Urate‐Lowering Therapy Clinical Trials for Gout Management
Arthritis &Rheumatology, EarlyView.
Lisa K. Stamp, Dien Ho, Nicola Dalbeth
wiley +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.In 21,459 acute ischemic stroke patients, Mendelian randomization found no shared genetic causal link between serum uric acid and epilepsy. Elevated admission uric acid was a robust risk marker for post‐stroke epilepsy in women but not men, with the apparent male protective association sensitive to stratification method.
Yan Cheng, Ji Li, Yunzhou Yang
wiley +1 more source
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
Arthritis Research & Therapy, 2019 Background For patients with recurrent flares of gout, tophi, urate crystal arthropathy, and renal stones, urate-lowering therapies (ULTs, including allopurinol and febuxostat) are the first-line treatment.
Amayelle Rey +6 more
doaj +1 more source
, 2023 Background: Febuxostat and allopurinol are the most commonly used uric acid-lowering medications, and their safety is of great concern, especially the cardiovascular adverse reactions associated with febuxostat.
Zhenwei Fang +6 more
core +1 more source